RNA Australia
RNA Australia is a NSW Government and five-university joint venture that operates Australia's first open-access GMP-grade RNA manufacturing facility, serving academic researchers, industry, and government with clinical-grade RNA production and ecosystem coordination services.
- Company typePrivate
- Founded2025
- HeadquartersSydney, Australia
- Headcount1–10
- GTM typeB2B
- OfferingServices
What RNA Australia does
RNA Australia is a joint venture between the NSW Government and five Australian universities — Australian National University (ANU), Macquarie University, University of New South Wales (UNSW), University of Sydney, and University of Technology Sydney (UTS) — structured to serve as the central hub of Australia's RNA therapeutics ecosystem. The entity was formally launched in 2024 and is headquartered at the Deep Tech Incubator at Macquarie University in Sydney. Its primary mandate is to oversee operation of the Pilot RNA Manufacturing Facility in Macquarie Park, NSW — Australia's first open-access GMP-grade RNA manufacturing facility, scheduled to open in 2026 — while coordinating research translation, industry engagement, and ecosystem development across the RNA value chain.
The company's core technology stack comprises end-to-end GMP-grade RNA manufacturing capabilities: plasmid DNA production, mRNA synthesis, liquid nanoparticle (LNP) formulation and delivery, fill and finish, integrated process development, and quality assurance and compliance. These capabilities are designed to serve applications in human health (mRNA vaccines and therapeutics), agriculture (RNA pesticides and crop protection), and biosecurity. Facility operations are handled in collaboration with Aurora Biosynthetics, a dedicated operator entity launched alongside RNA Australia. Beyond manufacturing, RNA Australia delivers four service lines: facility access (with discounted reserved access for university researchers and NFPs), ecosystem engagement (connecting researchers, industry, entrepreneurs, regulators, and investors), translation support (moving early research toward clinical readiness), and ecosystem intelligence (data, training, and insights).
Its business model is built on facility-access fees and ecosystem services within a public-sector/academic joint-venture framework. The company is privately held, pre-revenue (no disclosed funding rounds or revenue figures), operates with 1-10 employees, and does not pursue conventional commercial returns. Pricing is not publicly disclosed, and the primary customer segment is academic researchers, with secondary segments comprising industry partners, government/regulators (notably for pandemic preparedness), and investors/entrepreneurs. The operating geography is currently domestic — New South Wales, Australia — with no disclosed global footprint claims.
RNA Australia firmographics
Firmographics- Name
- RNA Australia
- Legal name
- RNA Australia Limited
- Website
- https://rnaaustralia.com.au
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RNA Australia is a NSW Government and five-university joint venture that operates Australia's first open-access GMP-grade RNA manufacturing facility, serving academic researchers, industry, and government with clinical-grade RNA production and ecosystem coordination services.
- Ownership category
- akta.pro rank
RNA Australia industry classification
Industry- Product category
- Biopharmaceutical Contract Manufacturing
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)
- akta.pro secondary industries
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market) (HLAAADAJ)
Keywords
Where RNA Australia is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
RNA Australia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Facility Access Fees: Revenue from providing access to the RNA manufacturing facility. Reserved access exclusively available to university researchers and NFPs at discounted rates, while broader ecosystem support is open to all participants.
- Ecosystem Services: Services supporting ecosystem development including connecting researchers, industry, entrepreneurs, regulators, and investors across the RNA value chain.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
RNA Australia product offering
Product offeringCore offering
RNA Australia operates as the central hub for Australia's RNA ecosystem, overseeing Australia's first open-access GMP-grade RNA manufacturing facility. The company provides facility access services to university researchers and non-profit research organizations, and offers ecosystem coordination services including translation support, stakeholder engagement, and ecosystem intelligence to advance RNA therapeutics, vaccines, and related technologies from research to clinical readiness.
Product overview
RNA Australia operates as a central hub organization for Australia's RNA ecosystem, offering a unified platform of services centered around the Pilot RNA Manufacturing Facility. The core offering consists of GMP-grade RNA manufacturing capabilities (operated in partnership with Aurora Biosynthetics) combined with ecosystem coordination services including facility access for university researchers and NFPs, translation support from research to clinical readiness, ecosystem engagement connecting stakeholders across the RNA value chain, and ecosystem intelligence providing data and training. The organization does not offer standalone software products but rather coordinates access to advanced RNA manufacturing capabilities and ecosystem support services.
Differentiator
Problem solved
Functional benefit
Products and services
- Pilot RNA Manufacturing Facility Australia's first open-access GMP-grade RNA manufacturing facility providing end-to-end manufacturing capabilities including Plasmid DNA Production, mRNA Synthesis, Liquid Nanoparticle (LNP) Formulation and Delivery, Fill and Finish, Integrated Process Development, and Quality Assurance and Compliance, designed to support development and production of RNA-based therapeutics, vaccines, and delivery technologies for clinical trials and commercialization.
- Facility Access Services Provision of GMP-grade RNA manufacturing facility access to university researchers and non-profit research organizations (NFPs), with reserved access exclusively available to these segments at discounted rates for development of RNA therapeutics, vaccines, and related technologies.
- Ecosystem Engagement Services Coordination and engagement services that connect researchers, industry, entrepreneurs, regulators, and investors across the RNA value chain to strengthen collaboration, translation, and commercialization of RNA-based innovations.
- Translation Support Services Services supporting RNA research from early-stage discovery through clinical readiness, helping drive RNA ideas into real-world outcomes and commercial applications for researchers, startups, and industry partners.
- Ecosystem Intelligence Services Data, training, and insights services providing ecosystem intelligence to help researchers, startups, and investors grow with confidence in the RNA therapeutics and biotechnology sector.
Companies that use RNA Australia
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
RNA Australia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature3 records
RNA Australia partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Aurora BiosyntheticscoreAurora Biosynthetics is the operator of the Pilot RNA Manufacturing Facility. The facility is operated in collaboration with Aurora Biosynthetics and designed to accelerate the development and production of RNA-based therapeutics, vaccines, and delivery technologies.
- NSW GovernmentcoreNSW Government is a joint venture partner in RNA Australia, providing funding and strategic support for the RNA ecosystem development. The government funds the Pilot RNA Manufacturing Facility and provides pandemic preparedness mandate.
- Australian National University (ANU)coreANU is one of five prestigious universities that are joint venture partners in RNA Australia, committed to supporting RNA research and ecosystem development.
- Macquarie UniversitycoreMacquarie University is one of five joint venture partner universities and hosts the Deep Tech Incubator where RNA Australia's headquarters is located, as well as the Pilot RNA Manufacturing Facility in Macquarie Park.
- University of New South Wales (UNSW)coreUNSW is one of five prestigious universities that are joint venture partners in RNA Australia, committed to supporting RNA research and ecosystem development.
- University of SydneycoreUniversity of Sydney is one of five prestigious universities that are joint venture partners in RNA Australia, committed to supporting RNA research and ecosystem development.
- University of Technology Sydney (UTS)coreUTS is one of five prestigious universities that are joint venture partners in RNA Australia, committed to supporting RNA research and ecosystem development.
Scale indicators3 records
Recent moves9 records
Expansion highlights6 records
RNA Australia competitors and assessment
Company assessmentEmerging players
- Vernal Biosciences: Vernal Biosciences is an emerging RNA-focused CDMO offering GMP-grade mRNA and LNP manufacturing. Directly comparable service offering but younger and US-based, similar to RNA Australia's pilot-stage positioning.
- eTheRNA immunotherapies: eTheRNA is an mRNA therapeutics company developing vaccines and immunotherapies with proprietary manufacturing capabilities. Comparable in mRNA technology stack but operates as a therapeutics developer with internal manufacturing.
Direct peers
- TriLink BioTechnologies (Maravai LifeSciences): TriLink provides mRNA synthesis, capping, and LNP formulation services for RNA therapeutics developers. Directly comparable in offering RNA manufacturing and formulation capabilities to clinical-stage customers.
- Aldevron: Aldevron (now part of Danaher) is a leading CDMO for plasmid DNA, mRNA, and proteins used in RNA therapeutics and vaccines. Directly comparable to RNA Australia's GMP-grade RNA manufacturing services and academic/biotech customer base.
Broad incumbents
- BioNTech: BioNTech is a leading mRNA therapeutics company with proprietary manufacturing capabilities and a broader therapeutic pipeline. Comparable in mRNA manufacturing expertise, though BioNTech also develops its own products rather than serving as a pure CDMO.
- Lonza: Lonza is one of the world's largest CDMOs with broad biomanufacturing capabilities including RNA and mRNA services. Comparable to RNA Australia in providing clinical-grade biomanufacturing, but at vastly greater global scale and breadth.
- CureVac: CureVac is an mRNA therapeutics company with in-house GMP manufacturing. Comparable in RNA technology and clinical development focus, though vertically integrated rather than a service provider like RNA Australia.
Regional players
- CSL Seqirus: CSL Seqirus is a major Australian-headquartered vaccine manufacturer with significant influenza and pandemic preparedness capabilities. Comparable as a domestically anchored Australian biomanufacturing player with a public-health mandate analogous to RNA Australia's pandemic-preparedness role.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
RNA Australia social profiles
Digital presenceRNA Australia financial estimates
Financial estimateRevenue estimate
Valuation estimate
RNA Australia leadership team
Management profileNumber of profiles
Profiles8 records
RNA Australia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RNA Australia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RNA Australia
What does RNA Australia do?
RNA Australia operates as the central hub for Australia's RNA ecosystem, overseeing Australia's first open-access GMP-grade RNA manufacturing facility. The company provides facility access services to university researchers and non-profit research organizations, and offers ecosystem coordination services including translation support, stakeholder engagement, and ecosystem intelligence to advance RNA therapeutics, vaccines, and related technologies from research to clinical readiness.
Is RNA Australia a public or private company?
RNA Australia is a private company. It is classified as state government owned and is currently operating.
When was RNA Australia founded?
RNA Australia was founded in 2025. It employs 1 to 10 people.
Where is RNA Australia based?
RNA Australia is headquartered in Sydney, Australia, in the Oceania region.
How does RNA Australia make money?
Two revenue lines are on record. Facility Access Fees are the primary driver. The others are ecosystem Services.
Who are RNA Australia's main competitors?
Emerging players on record are Vernal Biosciences and eTheRNA immunotherapies. Direct peers are TriLink BioTechnologies (Maravai LifeSciences) and Aldevron. Broad incumbents are BioNTech, Lonza and CureVac. CSL Seqirus is listed as a regional player.
Does RNA Australia have an API?
No public API is recorded for RNA Australia.
What industry is RNA Australia in?
RNA Australia's product category is Biopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC), with a secondary code of HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 541714 and its SIC code is 8731.